Chlorella powder (CP) has a hypocholesterolemic effect and high bile acid-binding capacity; however, its effects on hepatic cholesterol metabolism are still unclear. In the present study, male Wistar rats were divided into four groups and fed a high sucrose + 10% lard diet (H), an H + 10% CP diet (H þ CP), an H + 0.5% cholesterol + 0.25% sodium cholate diet (C), or a C + 10% CP diet (C þ CP) for 2 weeks. CP decreased serum and liver cholesterol levels significantly in rats fed C-based diets, but did not affect these parameters in rats fed H-based diets. CP increased the hepatic mRNA level and activity of cholesterol 7-hydroxylase (CYP 7A1). CP increased hepatic HMG-CoA reductase (HMGR) activity in the rats fed H-based diets, but not in rats fed C-based diets. CP did not affect hepatic mRNA levels of sterol 27-hydroxylase, HMGR, lowdensity lipoprotein (LDL) receptor, scavenger receptor class B1, ATP-binding cassette (ABC) A1, ABCG5, or ABCB11. Furthermore, the effect of a 3.08% Chlorella indigestible fraction (CIF, corresponding to 10% CP) on hepatic cholesterol metabolism was determined using the same animal models. CIF also decreased serum and liver cholesterol levels significantly in rats fed C-based diets. CIF increased hepatic CYP7A1 mRNA levels. These results suggest that the hypocholesterolemic effect of CP involves enhancement of cholesterol catabolism through up-regulation of hepatic CYP7A1 expression and that CIF contributes to the hypocholesterolemic effect.
cholesterol in plasma is a well-recognized risk factor for coronary heart disease.
1) The liver plays a key role in cholesterol homeostasis, involving the metabolism of LDL cholesterol. In the liver, the conversion of cholesterol to bile acids is a principle pathway of cholesterol catabolism, providing sufficient amounts of bile acids as detergents for the digestion and absorption of lipid nutrients and removing excess cholesterol from the body.
2) Cholesterol 7-hydroxylase (CYP7A1) is the rate limiting enzyme in the major biosynthetic pathway producing bile acids. Several dietary fibers have shown a cholesterol-lowering effect, enhanced the fecal excretion of bile acids and neutral steroids, and increased hepatic CYP7A1 activity in animal studies. [3] [4] [5] [6] Although the mechanism of this hypocholesterolemic effect is not fully understood, the ability to inhibit the intestinal absorption of bile acids and neutral steroids and enhance hepatic CYP7A1 activity plays an important role. Cholestyramine, a resin that strongly binds bile acids, is used as a hypocholesterolemic drug and remarkably enhances CYP7A1 activity. 3, 7) Overexpression of CYP 7A1 reduced the plasma LDL cholesterol concentration in mice lacking the LDL receptor gene. 8) Thus, upregulating the expression of CYP7A1 is thought to be one way of effectively lowering the serum cholesterol level.
Chlorella, a unicellular green alga grown in fresh water, was once developed as a protein source worldwide in the middle of the 20th century. Nowadays, Chlorella powder (CP) is used as a dietary supplement for several reasons. First, CP contains as much carotenoid and chlorophyll as green and yellow vegetables, and hence its ingestion is thought to improve diets low in vegetables and fruits. Second, it has been reported to have certain beneficial physiological effects, such as y To whom correspondence should be addressed. Fax: +81-42-577-3020; E-mail: shinya-shibata@yakult.co.jp Abbreviations: ABC, ATP-binding cassette; CB, cholesterol + bile acid; CIF, Chlorella indigestible fraction; CP, Chlorella powder; CYP7A1, cholesterol 7-hydroxylase; CYP27A1, sterol 27-hydroxylase; FXR, farnesoid X receptor; HDL, high density lipoprotein; HNF-4, hepatocyte nuclear factor 4; HMGR, HMG-CoA reductase; LDL, low-density lipoprotein; LDLR, LDL receptor; LRH-1, liver receptor homolog-1; LXR, liver X receptor ; PCR, polymerase chain reaction; SHP, short heterodimer partner; SR-B1, scavenger receptor class B1; SREBP-2, sterol regulatory element-binding protein 2; TG, triglyceride hypocholesterolemic, [9] [10] [11] [12] antihypertensive, 13) antioxidative, 14, 15) and anti-tumor 16, 17) activities in animal and human studies.
The hypocholesterolemic effect of Chlorella has been studied in various species of Chlorella, e.g., C. regularis, 9,10) C. vulgaris, 11) and C. pyrenoidosa. 12) However, the mechanism of the effect and the active components of Chlorella are not fully understood. Previously, we found that CP and an indigestible fraction of Chlorella had high bile acid-binding capacity in vitro and reduced serum and liver concentrations of cholesterol, decreased the concentration of fecal soluble bile acid, and enhanced the total amount of fecal neutral steroids in cholesterol-fed rats.
9) However, we did not determine the effect of CP on the rate of hepatic conversion of cholesterol to bile acids, i.e., the activity of CYP7A1. In addition, to elucidate further the mechanism by which CP decreases serum cholesterol levels, the effects of CP on the hepatic metabolism of cholesterol, e.g., synthesis of cholesterol (HMG-CoA reductase), transport of cholesterol (LDL receptor, scavenger receptor class B1, ATP-binding cassettes A1 and G5), and transport of bile acids (ATP-binding cassette B11) are needed. However, there has been no published study as to whether CP alters hepatic cholesterol metabolism in rats.
The aim of this study was to determine the effect of CP on the hepatic metabolism of cholesterol in rats, focusing on the enzymatic activity and mRNA levels of CYP7A1 and HMG-CoA reductase (HMGR), and the gene expression associated with the metabolism of cholesterol and bile acids (experiment 1). Furthermore, to clarify the active component of CP, the indigestible fraction of Chlorella (CIF), prepared as insoluble dietary fiber, was also examined using the same animal model (experiment 2). In addition, the roles of transcription factors and nuclear receptors in the metabolism of cholesterol in rats are discussed.
Materials and Methods
Materials. All chemical reagents whose sources are not indicated were purchased from Wako Pure Chemical (Osaka, Japan) except for the radioisotopes, which were obtained from American Radiolabeled Chemical (St. Louis, MO). The Chlorella powder (Chlorella regularis) was purchased from Nihon Chlorella (Tokyo).
Preparation of the Chlorella indigestible fraction (CIF). The procedure used to prepare CIF, which was examined in experiment 2, was based on a technique employed to determine insoluble dietary fiber, the enzymatic-gravimetric method established by the Association of Official Analytical Chemists (AOAC), 18) with some modifications. Viable Chlorella cells (Nihon Chlorella) were lyophilized, then defatted with chloroform:methanol (2:1, v/v) at room temperature for 24 h. The dried-defatted Chlorella cells (800 g) were suspended in 100-liter of phosphate buffer (0.08 M, pH 6.0) and incubated with 160 ml of -amylase (Termamyl 120L, Novozymes A/S, Bagsvaerd, Denmark) at 90 C for 30 min. After the solution had cooled to room temperature, its pH was adjusted to 7.5 with NaOH. The solution was incubated with 80 ml of protease (P4860, Sigma, St. Louis, MO) at 60 C for 30 min. The solution was cooled again to room temperature, and then the pH was adjusted to 4.3 with HCl. The solution was incubated with 160 ml of amyloglucosidase (A7095, Sigma) at 60 C for 30 min. After it was cooled to room temperature, the suspension was centrifuged at 1;000 Â g. The sediment was washed with water, centrifuged again, and freeze-dried (CIF). The yield of CIF was 30.8% from CP.
Animals and diets. Male Wistar rats (Japan Clea, Tokyo) aged 4 weeks were housed individually in stainless steel cages in a temperature-controlled (23 AE 3 C) room with 50 AE 10% humidity under a 12-h lightdark cycle (lights on 1500-0300). Thirty-two rats were fed a semipurified diet (AIN-76) prepared according to the formula recommended by the American Institute of Nutrition 19) ad libitum for 7 d. After this period of adaptation, they were separated into four groups of eight animals each having a similar mean body weight. The test diets are listed in Table 1 . Each group was fed one of the test diets and water ad libitum for 2 weeks. Food consumption was recorded every 2 or 3 d. The rats were weighed once a week. During the experiment, the animals were maintained in accordance with the regulations set down by the Ethics Committee for Animal Experiments of Yakult Central Institute. Experiment 1. The test diets in experiment 1 (Table 1) were a high sucrose and 10% lard diet (H), an H + 10% CP diet (H þ CP), an H + 0.5% cholesterol + 0.25% sodium cholate diet (C), and a C + 10% CP diet (C þ CP). All diets were designed to contain 20% digestible crude protein (nitrogen Â 6:25) and 11% fat. The digestibility of casein was defined as 100%. Digestible crude protein in CP was calculated using the following equation:
Digestible crude protein in CP = Crude protein in CP À Crude protein in the indigestible matter of CP.
The total amount of indigestible matter in a diet, i.e., cellulose and/or indigestible matter of CP, was set at 5%. Nitrogen levels were determined by the Kjeldahl method. Fat was analyzed according to the method of AOAC (the acid hydrolysis method).
18) The amount of indigestible matter of CP in experiment 1 was defined as the amount of dried residue obtained with the method used to determine the amount of total dietary fiber. 18) The amounts of crude protein (digestive), fat, and indigestible matter in CP were 407, 131, and 374 g/kg respectively. Experiment 2. The test diets in experiment 2 (Table 1) were H, the H + 3.08% CIF diet (H þ CIF), C, and the C + 3.08% CIF diet (C þ CIF). The amount of CIF (3.08%) in the diet corresponded to 10% CP, because the yield of CIF from CP was 30.8%. To balance nutrient levels between the test diets, CIF was replaced with cellulose. The level of crude fat remaining in CIF was 0.6%. The level of indigestible crude protein (nitrogen Â 6:25) in CIF was 50.8%.
Collection of samples. Rats were anesthetized with an intraperitoneal injection of pentobarbital sodium (Abbott Laboratories, Abbott Park, IL), of 50 mg/kg body weight. Serum was obtained from blood taken from the aorta ventralis between 0900 and 1100 h (dark phase 6-8 h). The liver was immediately removed, weighed, and used to isolate total RNA and prepare microsomes. A portion of the liver was stored at À20 C until lipid analysis.
Determination of serum and liver levels of lipids. Serum triglyceride and total cholesterol concentrations were measured enzymatically using a Hitachi 7170 automatic analyzer (Hitachi, Tokyo). The HDL cholesterol concentration in the serum was also determined enzymatically using a HDL cholesterol E-test (Wako). The liver was freeze-dried, and then lipids were extracted by the method of Folch et al. 20) The total cholesterol concentration in the liver was measured enzymatically using a Cholesterol E-test (Wako).
Preparation of liver microsomes (experiment 1).
A portion of liver (2 g) was quickly homogenized in icecold buffer (4 ml) containing 50 mM KCl, 2 mM MgCl 2 , 20 mM Tris-HCl (pH 7.6), and 250 mM sucrose in a Potter Teflon-glass homogenizer with four strokes. The homogenate was centrifuged, first at 1;000 Â g for 10 min and then at 12;000 Â g for 15 min. The supernatant was centrifuged at 105;000 Â g for 60 min. The resulting pellet was suspended in 150 mM KCl (pH 7.6) containing 1 mM EDTA. The microsomal preparation was stored at À70 C in a tightly sealed tube filled with nitrogen gas. The microsomal protein concentration was measured using a BCA protein assay kit (Pierce, Rockford, IL).
Hepatic cholesterol 7-hydroxylase (EC 1.14.13.17) assay (experiment 1). Hepatic cholesterol 7-hydroxylase activity was measured as the mass of 7-hydroxycholesterol formed from endogenous microsomal cholesterol. The procedure followed was that established by Chiang.
21) 7-hydroxycholesterol was converted to 7-hydroxy-4-cholesten-3-one (7HCO) enzymatically using cholesterol oxidase (C00-311, Toyobo, Osaka, Japan), and then 7HCO was extracted with ether. The concentration of 7HCO was determined by the method of Ogishima and Okuda 22) using normal phase HPLC (mobile phase, n-hexane:isopropanol = 82:18(v/v), flow rate, 0.8 ml/min, column, Finepak SIL-5 (4:6 Â 250 mm, Jasco, Tokyo), absorbance for detection, 240 nm, temperature, 25 C). 20-hydroxycholesterol (Steraloids, Newport, RI) was used as an internal standard.
Hepatic HMG-CoA reductase (EC 1.1.1.34) assay (experiment 1). The procedure followed was that established by Kuroda and Endo, 23) but with modifications. Briefly, the reaction mixture used to assay hepatic HMG-CoA reductase activity contained the following materials in a total volume of 100 ml: 0.1 mM DL-[3-14 C]3-hydroxy-3-methyl-glutaryl-CoA (160 Gbq/mol), 100 mM potassium phosphate buffer (pH 7.4), 10 mM EDTA, 10 mM dithiothreitol, 5 mM NADPH, and 0.2 mg of microsomal protein that was preincubated at 37 C for 20 min. After the enzymatic reaction, as an internal standard, 40 ml of 0.1 M [
3 H]mevalonolactone (5,000 dpm/ml) was added to each sample, and then the sample was incubated at 37 C for 15 min. After centrifugation, 40 ml of supernatant was applied to a plate of silica gel for TLC and developed in benzene:acetone (1:1, v/v). The mevalonolactone region of the gel was scraped off Quantitative gene expression analysis by real time PCR. RNA was isolated from rat liver using a SV Total RNA Isolation System (Promega, Madison, WI) according to the manufacturer's instructions. One micro-gram of total RNA was reverse transcribed in a final volume of 20 ml using a first-strand cDNA Synthesis Kit for RT-PCR (AMV) (Rosche Diagonistics, Indianapolis, IN) according to the manufacturer's directions. Real-time PCR amplification and detection were performed on an ABI PRISM 7500 system (Applied Biosystems, Foster city, CA) using SYBR Green technology. The reaction mixture was composed of 10 ml of SYBR Green Master Mix (Applied Biosystems), forward and reverse primers (100 mM, 0.2 ml each), 7.6 ml of nuclease-free water, and the cDNA sample (2 ml). The PCR primers used in the present study were described previously. 7) PCR plates (96 wells) were heated for 2 min at 50 C and for 10 min at 95
C. Subsequently, the PCR program consisted of 40 cycles of 15 s at 95 C and 60 s at 60 C. At the end of the run, a dissociation curve was obtained to check the specificity of the PCR. An adequate serial dilution of the cDNA sample was used to obtain a standard curve for each target gene, and the linear range of the standard curve (r 2 > 0:999) was used for the quantification. To normalize the differences in the amounts of cDNA between samples, glycelaldehyde-3-phosphate-dehydrogenase was used as a reference.
Statistical analysis. Measurements were expressed as the mean AE SD. Treatment effects (cholesterol + bile acid and CP or CIF) were analyzed by two-way ANOVA (SAS system version 8.2, SAS Institute, Cary, NC). When the interactions were significant, Tukey's multiple comparison tests (SAS system version 8.2) were performed. Differences were considered to be significant at P < 0:05.
Results

Experiment 1
Effects of Chlorella powder (CP) on the hepatic cholesterol metabolism in rats.
Food intake and body weight-gain CP tended to increase food intake (P ¼ 0:077) and increased body-weight gain (Table 2) . Cholesterol + bile acid (CB) decreased food intake, but did not affect body-weight gain.
Serum lipids CP tended to reduce the total concentration of cholesterol in serum (19%) in rats fed H-based diets, and reduced it significantly (62%) in rats fed C-based diets (Table 2) . CP decreased the concentration of HDL cholesterol in serum (24%) in rats fed H-based diets, but did not affect it in rats fed C-based diets. CP did not affect the concentration of triglyceride (TG). CB increased the concentration of cholesterol in serum, but decreased the concentrations of HDL cholesterol and TG. 
Body weight gain (g/ Liver weight and liver cholesterol concentrations CP increased liver weight in rats fed H-based diets, but not in rats fed C-based diets (Table 2) . Liver cholesterol concentrations were remarkably elevated in rats fed C-based diets, and were decreased by the administration of CP.
Activities of CYP7A1 and HMG-CoA reductase in the liver CP increased hepatic cholesterol 7-hydroxylase (CYP7A1) activity significantly ( Table 2) . CB also increased hepatic CYP7A1 activity significantly. CP increased hepatic HMG-CoA reductase (HMGR) activity in rats fed H-based diets, but did not affect this parameter in rats fed C-based diets. CB decreased hepatic HMGR activity.
Expression of CYP7A1, CYP27A1, HMG-CoA reductase, LDL receptor, and SR-B1 in the liver Hepatic CYP7A1 mRNA levels were increased by CP (Fig. 1) . CB and CP did not affect hepatic sterol 27-hydroxylase (CYP27A1) mRNA levels. CP tended to increase hepatic HMGR mRNA levels, but the differences were not significant (P ¼ 0:053). CP did not affect hepatic LDL receptor (LDLR) or scavenger receptor class B type 1 (SR-B1) mRNA levels. On the other hand, CB decreased hepatic HMGR and LDLR mRNA levels.
Expression of ATP-binding cassette (ABC) transporters
The hepatic gene expression of ATP-binding cassette (ABC) transporters, ABCA1, ABCB11, and ABCG5, related to the metabolism of cholesterol and bile acids, was not affected by CP (Table 3) . Hepatic ABCB11 and ABCG5 mRNA levels were increased by CB (Table 3) .
Expression of SREBP-2 and nuclear receptors regulating CYP7A1 expression in the liver
The mRNA level of SREBP-2, a transcription factor for HMGR and LDLR, was increased by CP in rats fed H-based diets, but was not affected by CP in rats fed Cbased diets (Table 3 ). The correlation between the mRNA levels of SREBP-2 and its targets, HMGR and LDLR, was significant (r ¼ 0:804, P < 0:001, and r ¼ 0:598, P < 0:001 respectively; both n ¼ 32). Hepatic mRNA levels of liver X receptor (LXR) and short heterodimer partner (SHP) did not differ among the groups (Table 3 ). The hepatic farnesoid X receptor (FXR) mRNA level was decreased by CB. CP slightly increased hepatic mRNA levels of liver receptor homolog-1 (LRH-1) and hepatocyte nuclear factor 4 (HNF-4), but the changes were not significant (P ¼ 0:111 and P ¼ 0:056 respectively).
Experiment 2 Effects of Chlorella indigestible fraction (CIF) on hepatic cholesterol metabolism in rats.
Food intake and body weight-gain CIF did not affect food intake or body weight-gain (Table 4) . CB decreased food intake and body-weight gain.
Serum lipids
CIF reduced the total concentration of cholesterol in serum (27%) in rats fed C-based diets, but did not affect this parameter in rats fed H-based diets (Table 4) . CIF increased the concentration of HDL cholesterol in serum. The effects of CB on the levels of total cholesterol, HDL cholesterol, and TG in serum were consistent with the effects of CB on these parameters in experiment 1. Experimental diets were high sucrose + 10% lard diet (H), H + 10% CP diet (H þ CP), H + 0.5% cholesterol + 0.25% sodium cholate diet (C), and C + 10% CP diet (C þ CP). Values are means AE SD (n ¼ 8).
a Abbreviations are described in ''Materials and Methods.'' NS, P > 0:05.
Liver weight and liver cholesterol concentrations CIF did not affect liver weight (Table 4) . Liver cholesterol concentrations were remarkably elevated in rats fed C-based diets, and were decreased by the administration of CIF.
Expression of CYP7A1, CYP27A1, HMGR, LDLR, and SR-B1 in liver
Hepatic CYP7A1 mRNA levels were increased by CIF (Fig. 2) . CB and CIF did not affect hepatic CYP27A1 mRNA levels. CIF increased hepatic HMGR mRNA levels. CIF did not affect hepatic LDLR or SR-B1 mRNA levels. CB increased hepatic CYP7A1 mRNA levels, but decreased hepatic HMGR, LDLR, and SR-B1 mRNA levels.
Expression of ABC transporters
The hepatic gene expression of ABCA1, ABCB11, and ABCG5 was not affected by CIF (Table 5) . Hepatic ABCB11 and ABCG5 mRNA levels were increased by CB, consistently with the results of experiment 1.
Expression of SREBP-2 and nuclear receptors regulating CYP7A1 expression in the liver
The mRNA level of SREBP-2 was not changed by CIF (Table 5) . CB decreased hepatic mRNA levels of SREBP-2. There was a significant positive correlation between the mRNA levels of SREBP-2 and HMGR (r ¼ 0:824, P < 0:001, n ¼ 32), and between the mRNA levels of SREBP-2 and LDLR (r ¼ 0:821, P < 0:001, n ¼ 32). Hepatic mRNA levels of LXR and FXR did a H, high sucrose + 10% lard diet; H þ CIF, H + 3.08% CIF diet; C, H + 0.5% cholesterol + 0.25% sodium cholate diet; C þ CIF, C + 3.08% CIF diet. Values are means AE SD (n ¼ 8). When the interactions were significant by two-way ANOVA, Tukey's multiple comparison test was conducted. Means within a row followed by the same letter are not significantly different by Tukey's multiple comparison test (P < 0:05).
not differ among the groups. The hepatic SHP mRNA level was increased by CB. Hepatic LRH-1 mRNA levels were greater in rats fed the C þ CIF than in rats fed the H or the H þ CIF diet. CIF increased hepatic mRNA levels of HNF-4 in rats fed the C-based diets.
Discussion
The present study indicates that CP and CIF stimulated the hepatic gene expression of CYP7A1 in rats with or without diet-induced hypercholesterolemia. We also confirmed that the activity of CYP7A1 was increased by CP ( Table 2 , experiment 1). Hence, we conclude that ingestion of CP increases the conversion of cholesterol to bile acids in the rat liver. In experiment 1, a significant positive correlation between mRNA levels and the activities of CYP7A1 was observed (r ¼ 0:404, P ¼ 0:022, n ¼ 32). These results are consistent with another study, which showed that changes in the activity of CYP7A1 are associated with parallel changes in the mRNA levels of CYP7A1 in the rat liver. 24) Hence, in experiment 2, we measured only the gene expression of CYP7A1, instead of microsomal enzyme activity.
The hypocholesterolemic effect of dietary fiber might be mediated by increases in the size of the pool of bile Experimental diets were, high sucrose + 10% lard diet (H), H + 3.08% CIF diet (H þ CIF), H + 0.5% cholesterol + 0.25% sodium cholate diet (C), and C + 3.08% CIF diet (C þ CIF). Values are means AE SD (n ¼ 8).
a Abbreviations are described in ''Materials and Methods.'' NS, P > 0:05. 26) In a previous study, cholestyramine increased the hepatic activities of HMGR and CYP7A1 in rats fed H-based diets, and increased only the activity of CYP7A1 in rats fed C-based diets. 7) Although we did not determine the intestinal pool size or fecal excretion of steroids in the present study, our previous study indicate that CP and its indigestible fraction increased the total amount of fecal steroids in cholesterol-fed rats.
9) Hence, we speculate that up-regulation of CYP7A1 by CP and CIF is due to their ability to inhibit intestinal absorption of bile acids and/or neutral steroids.
CP increased the hepatic catabolism and synthesis of cholesterol in rats fed H-based diets. Nevertheless, it did not affect hepatic LDLR mRNA levels (Fig. 1) . It is well established that the gene expression of LDLR is regulated by the level of hepatic cholesterol; cholesterol down-regulates the expression. However, Spady and Cuthbert have reported that a cholesterol-enriched diet markedly suppressed hepatic cholesterol synthesis, increased bile acid synthesis, and did not affect LDL receptor activity in rats. 24) In addition, changes in LDLR mRNA levels were not correlated with changes in LDLR activity in rats. 24) In a previous report, cholestyramine increased hepatic CYP7A1 and HMGR activities, but increased hepatic LDLR mRNA levels only slightly. 7) As described above, since the LDLR-mediated pathway is not a key regulatory pathway in the maintenance of cholesterol homeostasis in the rat liver, the cholesterollowering effects of CP and CIF may not have been dependent on the LDLR-mediated pathway in the present experiments. However, a positive correlation between SREBP-2 and HMGR mRNA levels and between SREBP-2 and LDLR mRNA levels was observed in experiments 1 and 2. Thus the present results suggest that ingestion of CP and CIF can potentially up-regulate HMGR and LDLR expression via a SREBP-2-mediated pathway.
In the present study, CP and CIF did not affect the hepatic gene expression of CYP27A1, SR-B1, ABCA1, ABCB11, or ABCG5. Cholestyramine did not affect hepatic mRNA levels of CYP27A1, SR-B1, ABCA1, or ABCB11, and it decreased that of ABCG5 in a previous study. 7) Recent research indicates that changes in ABCG5 expression are associated with changes in hepatic cholesterol levels, but CP and CIF did not affect the hepatic gene expression of ABCG5, although they decreased hepatic cholesterol levels in rats fed C-based diets. One explanation for this is that the changes in hepatic cholesterol levels caused by CP and CIF were not as great as those in other studies. 7, 27) Recently, much attention has focused on the roles of nuclear receptors in the metabolism of cholesterol and bile acids. 2) In rats, cholesterol stimulates the transcription of CYP7A1 via activation of the oxysterol receptor, LXR. Bile acids negatively regulate the transcription of CYP7A1 via the activation of FXR, i.e., a SHP-dependent pathway, and by a SHP-independent pathway affecting HNF-4, a positive transcription factor for CYP7A1. In the present study, hepatic LXR mRNA levels were not changed by either treatment. Moreover, hepatic mRNA levels of ABCA1 and ABCG5, known as LXR-activated genes, and of SHP and ABCB11, known as FXR-activated genes, were not changed by CP or CIF. Hence, these results suggest that CP and CIF up-regulate the expression of CYP7A1 independently via an LXR or an FXRmediated pathway in rats. Previously, we also found that cholestyramine up-regulates the expression of CYP7A1 independently via a LXR-or FXR-mediated pathway using the same animal model. 7) Recent research suggests that HNF-4 plays an important role in the up-regulation of CYP7A1 expression in cholestyramine-treated patients with gallstone disease 28) and in cerebrotendinous xanthomatosis patients. 29) In two human studies, increases in CYP7A1 mRNA levels were accompanied by increases in HNF-4 mRNA levels, but FXR and SHP were normally expressed. 28, 29) Thus these studies suggest that the pathway via HNF-4 regulates CYP7A1 over the FXR/SHP-dependent pathway. The present results did not clearly show an increase in HNF-4 mRNA levels in rats fed CP or CIF, but revealed a tendency towards an increase in HNF-4 mRNA levels caused by CP (P ¼ 0:056), and a significant increase in HNF-4 mRNA levels in rats fed the C þ CIF diet as compared to those in rats fed the C diet. In addition, HNF-4 mRNA levels were positively correlated with CYP7A1 mRNA levels in experiments 1 and 2 (r ¼ 0:552, P ¼ 0:001, n ¼ 32, and r ¼ 0:413, P ¼ 0:019, n ¼ 32 respectively).
In general, soluble fibers, e.g., pectin, psyllium, and oat gum, are recognized to be effective in lowering serum cholesterol concentrations, whereas insoluble fibers are not. 30) Pectin, psyllium, and oat gum have been reported to have hypocholesterolemic effects in rats with concentrations ranging from 3% to 10% of diets. 30) In the present study, CIF exerted a hypocholesterolemic effect in rats when it comprised 3.08% of the diet. Thus the present results indicate that CIF has a hypocholesterolemic activity similar to soluble fibers with a potent serum cholesterol-lowering effect.
Phospholipids and glycolipids extracted from Chlorella have been reported to have hypocholesterolemic effects in rats, 11, 31) but, the mechanisms underlying these cholesterol-lowering effects are still unclear. A diet enriched with 20% soybean lecithin caused only a 17% increase in hepatic CYP7A1 activity in rats. 32) To our knowledge, the effect of glycolipids on CYP7A1 activity in rats is unknown. Previously, we found that the indigestible fraction of Chlorella had a greater capacity to bind bile acids in vitro than did CP on a dry weight basis. 9) Here we confirmed that CIF is also capable of binding bile acids (data not shown). Taken together, it appears likely that CIF is the component in CP most responsible for the binding of bile acids and the upregulation of CYP7A1 expression. The hypocholesterolemic effect of fermentable dietary fiber might be mediated by short-chain fatty acids produced by intestinal bacteria. 33, 34) Fabier et al. have reported that fermentable carbohydrates have a more potent cholesterol-lowering effect than cholestyramine. 35 ) Although we did not determine whether CP or CIF influenced the production and distribution of shortchain fatty acids in the intestine, short-chain fatty acids might be responsible for the hypocholesterolemic effects of CP and CIF.
In conclusion, the present study suggests that CP enhances the hepatic degradation of cholesterol by upregulating the expression of CYP7A1 in rats with or without diet-induced hypercholesterolemia. Based on our data on hepatic enzyme activities and gene expression profiles, induction of CYP7A1 expression might be the most important mechanism in the liver contributing to the hypocholesterolemic effect of CP. The active component in CP responsible for the upregulation of CYP7A1 expression might in part be the indigestible fraction.
